We got here throughout a bullish thesis on Syndax Prescribed drugs, Inc. on BioEquity Watch’s Substack. On this article, we’ll summarize the bulls’ thesis on SNDX. Syndax Prescribed drugs, Inc.’s share was buying and selling at $20.67 as of January fifteenth.
Phovoir/Shutterstock.com
Syndax Prescribed drugs has transitioned right into a commercial-stage biotech anchored by two first-in-class permitted therapies, Revuforj (revumenib) and Niktimvo (axatilimab), every addressing areas of excessive unmet medical want. Revuforj is an oral Menin inhibitor permitted for relapsed or refractory acute leukemias with KMT2A rearrangements, the place disruption of the Menin–KMT2A interplay shuts down oncogenic gene expression and drives leukemic cell differentiation and dying.
Constructing on this approval, Syndax is pursuing enlargement into NPM1-mutant AML through a supplemental NDA supported by AUGMENT-101 information, whereas additionally advancing frontline mixture research that might meaningfully broaden its addressable market. Niktimvo, an anti-CSF-1R monoclonal antibody permitted for closely pretreated continual graft-versus-host illness, targets macrophage-driven irritation and fibrosis, providing a differentiated mechanism versus current therapies. Its pipeline enlargement into IPF and mixture regimens in cGVHD additional extends its long-term potential.
Financially, Syndax is effectively capitalized, with roughly $518 million in money and investments as of Q2 2025. Revuforj is displaying sturdy early business traction, producing $28.6 million in quarterly web income with sequential development, whereas collaboration income from Incyte helps Niktimvo’s launch. Though the corporate stays loss-making as a consequence of elevated R&D and business spending, administration expects current money and rising revenues to fund operations by profitability.
Strategically, Syndax advantages from first-mover benefit in Menin inhibition, publicity to genetically outlined leukemia populations with restricted competitors, and income diversification throughout oncology and immune-mediated ailments. With late-2025 regulatory catalysts, increasing scientific packages, and rising business adoption, Syndax presents a compelling long-term development alternative pushed by execution throughout its two cornerstone property.
Beforehand, we lined a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) by Magnus Ofstad in January 2025, which highlighted the corporate’s management in Duchenne muscular dystrophy, accelerating revenues, and acquisition attraction. SRPT’s inventory worth has depreciated by roughly 81.94% since our protection as a consequence of security considerations and regulatory uncertainty round Elevidys. BioEquity Watch shares the same view however emphasizes on business execution and first-in-class hematology property at Syndax Prescribed drugs.
